PREVENTION OF ANTRACYCLIN ANTIBIOTIC DOXORUBICIN СARDIOTOXICITY: A ROLE OF ACE-INHIBITOR PERINDOPRIL

Aim – to study how anthracyclines influence on cardiovascular system in patients with lymphomas and whether angiotensin-converting enzyme inhibitor Perindopril is cardioprotective in these patients.

Subjects and methods. 26 patients with Hodgkin’s disease and non-Hodgkin’s lymphomas were followed before and after treatment with
doxorubicin. 12 of these patients with arterial hypertension received angiotensin-converting enzyme inhibitor Рerindopril, 10 mg/d, during
treatment with doxorubicin. Cardiological evaluation was performed before and the next day after chemotherapy. Average dose of Doxorubicin was 34,99 ± 13,23 mg/m2.

Results. In patients receiving anthracyclines deceleration time DT increased significantly, a significant reduction in heart rate (HR), cardiac
output (CO) and cardiac index (CI) were observed also (рDT = 0,037, pHR = 0,048, рСО = 0,007, рCI = 0,007). In patients simultaneously
treated with Perindopril these parameters were not statistically different (рDT = 0,92, pHR = 0,22, рCO = 0,35, рCI = 0,39).

Conclusion. Administration of anthracyclines (average dose of Doxorubicin 34,99 ± 13,23 mg/m2) leads to DT of the left ventricle and
reduction in HR, CJ and CI. Simultaneous treatment with Perindopril in patients receiving anthracyclines preserves DF and prevents heart hemodynamics abnormalities.

1. Российская Федерация: Федеральная служба государственной статистики. URL: http://www.gks.ru

2. Всемирная организация здравоохранения. URL: http://www.who.int/features/qa/15/ru/index.html

3. Химиотерапия опухолевых заболеваний. Краткое руководство. Под ред. Н.И. Переводчиковой. М., 2000.

4. Ewer M.S., Benjamin R.S. Cardiotoxicity of chemotherapeutic drugs. In: The chemotherapy source book. M.C. Perry, ed. Lippincott Williams & Wilkins, 1997. P. 649–63.

5. Zambetti M., Moliterni A., Materazzo C., et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37–43.

6. Cardinale D., Colombo A., Sandri M. et al. Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–81.

7. Jensen B.V., Nielsen S.L., Skovsgaard T. Treatment with angiotensin-convertingenzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996;347:297–9.

8. Silber J.H., Cnaan A., Clark B.J. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004;22:820–8.

9. Okumura K., Jin D., Takai S., Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002;88:183–8.

10. Tokudome T., Mizushige K., Noma T. et al. Prevention of doxorubicin (adriamycin)- induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000;36:361–8.

11. Ершов В.И., Литвицкий П.Ф., Кочкарева Ю.Б. Свободнорадикальные перикисные процессы и кардиотоксичность при лечении злокачественных лимфом. Клиническая медицина 2006;(9):47–51.

12. Chopra M., Beswick H., Clapperton M., et al. Antioxidant effects of angiotensinconverting

13. enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydrylcontaining ACE inhibitors. J Cardiovasc

14. Pharmacol 1992;19:330–40.

15. Шевченко Ю.Л., Бобров Л.Л., Обрезан А.Г. и др. Изменения диастолической функции левого желудочка сердца у больных лимфогранулематозом. Клиническая медицина 2001;(6):20–3.

16. Ватутин Н.Т., Калинкина Н.В., Кетинг Е.В. и др. Изменения функционального состояния левого желудочка при воздействии антрациклиновых антибиотиков. Кардиология 2001;(6):46.

17. Шевченко Ю.Л., Бобров Л.Л., Новик А.А. и др. Изменение диастолической функции левого желудочка сердца у больных с неходжкинскими лимфомами. Кардиология 2001;(9):51–5.

18. Fujita N., Hiroe M., Ohta Y. et al. Chronic effects of metoprolol on myocardial j3-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol 1991;17:656–61.

19. Robison T.W., Giri S.N. Effects of chronic administration of doxorubicin on myocardial j3-adrenergic receptors. Life Sci 1986;39:731–6.

20. Tong J., Ganguly P.K., Singal P.K. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 1991;260(3 Pt 2):909–16.